Actively Recruiting
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
Led by Vanderbilt University Medical Center · Updated on 2026-01-20
60
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
Sponsors
V
Vanderbilt University Medical Center
Lead Sponsor
A
American Heart Association
Collaborating Sponsor
AI-Summary
What this Trial Is About
The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections. This syndrome affects mostly women (\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and "brain fog", commonly described in POTS patients are also present in this novel condition, recently named post-COVID-19 tachycardia syndrome, POTS variant. Reduced Vagal activity and unresolved inflammation is post-COVID-19 POTS is hypothesized as the cause of Long COVID
CONDITIONS
Official Title
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prior RT-PCR-confirmed COVID-19 infection
- Presence of orthostatic tachycardia greater than 30 bpm and chronic pre-syncopal symptoms lasting more than 3 months indicating post-COVID-19 POTS
You will not qualify if you...
- History of heart disease such as myocardial infarction, angina, or heart failure
- History of stroke or transient ischemic attack
- Previous invasive cardiovascular procedures including bypass graft, angioplasty, valve replacement, pacemaker, or vascular surgeries
- Uncontrolled hypertension with blood pressure consistently over 140/90
- Post-menopausal women
- Diabetes Mellitus Type 1 or Type 2
- Impaired liver function
- Impaired kidney function with eGFR less than 60 mL/min/1.73m2
- Ongoing substance abuse
- Mental health conditions preventing understanding of the study
- History of seizures
- Chronic use of steroids or NSAIDs
- Use of biologics such as anti-IL6 (omalizumab) or anti-TNF-alpha drugs
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
Research Team
M
Meena Vinayagam, M.D.
CONTACT
C
Cyndya Shibao, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here